Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6604218.pdf
Reference11 articles.
1. Bachelot T, Ray-Coquard I, Catimel G, Ardiet C, Guastalla JP, Dumortier A, Chauvin F, Droz JP, Philip T, Clavel M (2000) Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase-I clinical trials. Ann Oncol 11: 151–156
2. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461–3467
3. Cox DR (1972) Regression models and life tables. J Roy Stat Soc (B) 34: 187–202
4. Han C, Braybrooke J P, Deplanque G, Taylor M, Mackintosh D, Kaur K, Samouri K, Ganesan TS, Harris AL, Talbot DC (2003) Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 89: 1166–1171
5. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ, Grady C (2005) Risks and benefits of phase-1 oncology trials, 1991 through 2002. N Engl J Med 352: 895–904
Cited by 150 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram;Frontiers in Immunology;2024-01-15
2. Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma;Cancer Biomarkers;2023-11-20
3. Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE;European Journal of Cancer;2023-08
4. Assessing the role of colonic and other anatomical sites uptake by [18F]FDG‐PET/CT and immune‐inflammatory peripheral blood indexes in patients with advanced non‐small cell lung cancer treated with first‐line immune checkpoint inhibitors;Thoracic Cancer;2023-07-13
5. Profile and outcome of cancer patients enrolled in contemporary phase I trials;European Journal of Cancer;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3